ERC has opened a new additional production site in the Netherlands dedicated to GMP-based production of Gliovac/ERC1671/SITOIGANAP against glioblastoma brain cancer, as well as vaccines based on the same, patented technology targeting other types of tumours. The New site is situated in a biotech-focussed area of Kerkenbos in the University city of Nijmegen.
